Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of filibuvir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve HCV genotype 1 infection
2009-009214-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing Filibuvir + Pegasys + Copegus with Placebo + Pegasys + Copegus (2 arms). Primary endpoint: Sustained virologic response at Week 72. Started May 2009; status: completed.
02
Drugs
filibuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-009214-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009214-40.